NIT
EGRX

NumerixS Investment Technologies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

NumerixS Investment Technologies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-700
Closed -$39K – 1285
2019
Q2 		$39K Buy
+700
New +$36.5K 0.01% 818

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

NumerixS Investment Technologies's EGRX Position: Q3 2019 in Review

NumerixS Investment Technologies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2019, closing a stake of 700 shares — an estimated $39K sold.

NumerixS Investment Technologies first reported a position in EGRX in Q2 2019 and held it in 1 quarter. The position peaked at $39K in Q2 2019. 183 funds tracked by Wall St. Rank hold EGRX as of Q3 2019.

  • NumerixS Investment Technologies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • NumerixS Investment Technologies sold 700 Eagle Pharmaceuticals, Inc. shares in Q3 2019, an estimated $39K.
  • NumerixS Investment Technologies first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • NumerixS Investment Technologies's Eagle Pharmaceuticals, Inc. position peaked at $39K in Q2 2019.
  • 183 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2019.

Based on NumerixS Investment Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.